The aim of this prospective study is to assess the natural history of these changes in patients with peptic ulcer and non-ulcer antral chronic atrophic gastritis.
at the start of the study. In the six year period to 1988 a total of 241 biopsies were performed on the patients with chronic atrophic gastritis and 243 on the patients with gastric ulcer. Initially, 81% of the patients with chronic atrophic gastritis presented with type I intestinal metaplasia and 14% with type II intestinal metaplasia. During follow up type I was predominant, often associated with grades 2 and 3 active disease (81%) and 45% of these patients reverted to a non-intestinal metaplasia status by the third year of follow up. In contrast, type III metaplasia was more common in the absence of appreciable inflammation (78% of biopsy specimens), being persistent in five of seven patients in the third year of follow up, and was found to be associated with dysplasia in three of these patients. Similarly, the initial biopsy specimen showed type I metaplasia in most patients with gastric ulcer (82%) and type III in only 4%. Type I metaplasia was also predominant in these patients (80%), particularly in active disease (68%), gradually regressing with healing. In contrast, type III was associated with delayed ulcer healing and reactivation (75%; six of eight patients). We conclude that (a) type I is a short term reactive process which regresses with healing; (b) type III is related to prolonged injury and chronicity and may regress or progress to dysplasia; (c) persistent and more immature forms of metaplasia may carry an increased risk of malignancy. different types of chronic gastritis and intestinal metaplasia.
At least three distinct aetiopathological types of chronic gastritis are now recognised: 'autoimmune,' 'hypersecretory,' and 'environmental,' which is relevant to this study. It involves the incisura angularis and the antrum and can progress to intestinal metaplasia and is associated with an increased risk ofthe 'intestinal' type of gastric carcinoma and peptic ulcer. 4 Three variants of intestinal metaplasia have been identified.5 A close relation between the variant characterised by incomplete cell differentiation and sulphomucin secretion (type III intestinal metaplasia or 'colonic' type) and gastric carcinoma of intestinal type has been suggested, while other non-sulphated variants (types I and II or 'small intestinal' type) are predominant where the risk of cancer is low."8 If this is so, the presence of atrophic gastritis and sulphomucins in intestinal metaplasia (type III) in a gastric biopsy specimen may indicate increased cancer risk. '2 More information is needed on the rate of progression or improvement of chronic gastritis and its association with the evolution ofintestinal metaplasia. A change of type of metaplasia may signal an increased risk ofsubsequent carcinoma. These evolving changes can only be assessed by a series of biopsies over several years.
The aim of this prospective study is to assess the natural history of these changes in patients with peptic ulcer and non-ulcer antral chronic atrophic gastritis.
Retrospective material from an unplanned follow up of 118 patients with chronic gastritis and peptic ulcer is also included to evaluate sampling error and reliability of biopsy interpretation. (Table I) A total of 241 biopsies were carried out in 58 patients with histologically proved chronic gastritis."3 The antrum was sampled in all patients and in some cases additional biopsy specimens were taken from the body (n= 15) or incisura angularis (n=6). These patients were followed up for two years (n= 58), three years (n=41), four years (29) , incisura angularis (26) , and body (14) . Three In the gastric ulcer group there were 31 men and 12 women (M/F 2-5) with a mean age of 50 and 57 years respectively. Biopsy specimens were taken from the ulcer border in the antrum (65%), body (20%), and incisura angularis (15%).
The chronic gastritis patients consisted of 44 men and 31 women (M/F 1-4) with a mean age of 53 and 56 years respectively. Biopsy specimens *Severity of inflammation.
Percentage of total number of biopsy specimens in each degree of gastritis in parentheses.
were taken from the antrum (54%), body (34%), and incisura angularis (12% 1st (58) 2nd (58) 3rd (41) 4th (19) 5th ( Degree ofinflammation and types ofintestinal metaplasia The majority of the biopsy specimens (53%) taken from these patients during up to six years of follow up showed a moderate degree of inflammation (grade 2). Severe active inflammation was present in only 21%, the remaining 63 biopsy specimens being grade 1. Intestinal metaplasia, present in the initial biopsy specimen, was also found in 177 of the follow up specimens (73%). Type I intestinal metaplasia was predominant (77%), while type III was seen in 16% of the intestinal metaplasia positive biopsy specimens. Type I was more often associated with severe active and moderate inflammation (81%), whereas type III was more common in the absence ofappreciable inflammation (78%) and rarely found in severe active gastritis (11%). The number of specimens showing type II was too small to be conclusive (Table  II) .
Dysplasia, found in six biopsy specimens from three patients, was associated in all cases with type III intestinal metaplasia, representing 37-5% of the patients in this category during follow up.
Evolution ofintestinal metaplasia in biopsy specimens duringfollow up (Table III) The majority of the 58 patients with chronic gastritis presented with type I intestinal metaplasia in the initial biopsy (81%), types II and III being found in 5% and 14% respectively. Patients with type I remained unchanged (61%) or reverted to a 'no intestinal metaplasia' status (34%) in the second year, and by the third year 21 patients showed no metaplasia (45%). None of the patients in this group developed type III metaplasia during the follow up period.
In contrast, in the type III group, this lesion persisted in five out of seven patients during the third year of follow up, and was found to be associated with dysplasia in three. One of these patients has now been followed up for six years, with biopsy specimens showing type III metaplasia and dysplasia, and another developed a small ulcer. In this group an additional patient, who refused follow up, developed carcinoma five years after the initial biopsy (Table III) .
Intestinal metaplasia and the pattern ofevolution ofgastritis (Table IV) Analysis of the follow up biopsy material suggests three broad patterns ofevolution ofseverity and activity of inflammation: unchanged (n=41), worse (n=10), or improved (n=7). In Table IV suggest differing patterns ofevolution of types I and III metaplasia in patients. Type III occurred in patients with a persistent unchanged gastritis (group B), which in all but one showed only a mild/moderate degree of inflammation, a variable degree of glandular atrophy, and slight fibrosis in two. The one patient in this group presenting with severe gastritis later developed an ulcerative lesion and has since been lost to follow up. As mentioned above, all three patients with dysplasia are in this group.
Fewer patients with an unchanged pattern of gastritis and type I metaplasia (group A) seem to regress to a 'no intestinal metaplasia' status when compared with the overall pattern of the type I group as shown in Table III (9% and 34% respectively for the second year follow up).
Three patients in the 'worse' category later developed peptic ulcer (one) and erosions (two), but neither these nor four others showed metaplasia in the follow up biopsy specimens.
Five of the six patients with initial type I metaplasia reverted to a 'no intestinal metaplasia' status as the inflammatory process 'improved' during the follow up period.
Biopsy site and pathology
In 58 patients samples were taken from the antrum in both the first and subsequent biopsies. The gastric pathology described above refers largely to the antrum. In 20 patients additional biopsy material was taken from the body (n= 14) and incisura angularis (n=6). The body mucosa was rarely involved (3/14) irrespective of the degree of changes in the antrum, while the changes in the incisura angularis matched those in the antrum. I (Table V) .
Intestinal metaplasia and the evolution ofgastric ulcer duringfollow up of66 patients The initial biopsy specimen taken from the ulcer border showed type I metaplasia in most patients with gastric ulcer (82%), with only a few showing types II (14%) and III (4%). Eight patients (12%) developed type III during follow up (Table VI) . In contrast to chronic gastritis, intestinal metaplasia types in gastric ulcer seem to show greater variation during follow up. In the second year, though the majority of type I patients presented with either type I (57%) or no metaplasia (39%), type III was detected in one patient and in two further patients in the third and fourth years of follow up. Similarly, in the group with type II metaplasia two out of nine patients presented with type III in the second year. In one of these patients type III persisted with recurrent ulceration, and subsequently gastrectomy showed extensive intestinal metaplasia but no malignancy. Subsequent biopsy specimens in the initial type III patients showed type I metaplasia in one and 'no metaplasia' in the other two (Table  VI) .
To clarify these observations we looked at the correlation between types of intestinal metaplasia and delayed healing, or reactivation of the ulcer.
Correlation between types of intestinal metaplasia and delayed healing or reactivation ofthe ulcer (Table VII) In the gastric ulcer group 33 patients showed subsequent reactivation of the ulcer or a delayed healing process. The initial biopsy specimen from the ulcer border in this group of patients showed type I metaplasia in 27, and in the remaining six either type II (five) or type III (one). During follow up six patients developed type III at some stage independently of the type of metaplasia present in the initial biopsy specimen. This group accounts for 75% of patients with type III (six of eight) in the whole gastric ulcer group. Follow up biopsy specimens from three of these patients showed type I or no metaplasia. A scar was seen at endoscopy on a fourth patient and two patients were lost to follow up (Table VII) This uncertainty concerning the prognostic importance of gastritis and metaplasia raises a number of questions which are, as yet, unanswered. (1) Is the risk factor in severe atrophic gastritis, as measured by the degree of glandular atrophy, independent of the presence of intestinal metaplasia or the type of metaplasia, or both? (2) Is the risk factor related to a particular pattern ofevolution of the disease? (3) Do types I and III metaplasia reflect different stages in the evolution of chronic atrophic gastritis?
The first question prompts the need for standardised morphological criteria for the classification of chronic atrophic gastritis. Our criteria were based on the presence of intestinal metaplasia and the degree and activity of inflammation. It is broadly similar to Whitehead's classification'3 but differs from that proposed by the Finnish group.'7 The latter used the degree of glandular atrophy independent of both intestinal metaplasia and inflammation. The argument for a single criterion is easy classification and application to mathematical models and that atrophy can occur in the absence of metaplasia. It excludes, however, morphological features which provide information on the evolution of the disease and the host response to stimuli, which together play a part in the outcome of the process. We do not know why in some cases the gastric epithelium reacts to 'injury' by simple loss of gastric glands, while in others aberrant regeneration occurs, leading to intestinal epithelium in all its variants. Different pathways ofresponse may be involved. Furthermore, glandular atrophy is easy to identify in its more advanced forms, but mild atrophy (and Cheli's pre-atrophic gastritis'8) is subjective and thus not applicable for multicentre or comparative studies. Though its importance is not clear, we believe that intestinal metaplasia is an important feature and should be included in the classification of chronic gastritis, together with inflammation and epithelial and glandular changes.
Another aspect to consider in follow up studies is the reliability of biopsy material in assessing the evolution of disease, in terms of endoscopic interpretation and topographical variations. This difficulty has been minimised in the present (Table  III) . Furthermore, it is interesting that the return to non-metaplasia status was less common in patients presenting with unchanged persistent gastritis (6/3 1) compared with those in whom the condition 'worsened' or 'improved' (13/17). In contrast type III is often associated with nonactive, moderate, or quiescent gastritis and atrophy, and all eight patients presented an unchanged pattern of gastritis during follow up.
These observations suggest that type I is perhaps an early event in response to an irritant. On the other hand, type III seems to be related to chronicity. The persistent action of mucosal irritants can lead to progression ofchanges: from well differentiated type I to more immature or aberrant phenotypes'9 characterised by sulphomucin secretion,5 expression of fetal20 and intestinal type antigens,21 22 and a high proliferative index seen in variants of intestinal metaplasia including type III and dysplasia. 2324 Similarly, in patients with gastric ulcer a relation between type I and active disease was apparent, while type III seemed to be independent of the course and more common in delayed ulcer healing or reactivation (75%, 6/8 patients).
The importance of the more immature phenotype of intestinal metaplasia in association with gastric ulcer is not yet known, and one can only speculate. The precise risk of malignancy in gastric ulcer is poorly evaluated2526 but it is reported to be less than 1%. 27 Type I metaplasia seen in the border of 80% of active gastric ulcers can be interpreted as a reactive process to gastritis, whereas type III metaplasia seems to be related to a long process ofinjury with repeated episodes ofinflammation, regeneration, and repair, higher proliferative activity, and greater numbers of immature cells. These patients may be at an increased risk of malignancy. In our series of 26 early gastric carcinomas 23 presented as peptic ulcers, and in 18 type III metaplasia was seen in the preceding biopsy specimens or in the resected specimens, or both. 28 Of interest, a recent British survey of early gastric carcinoma29 has shown that symptoms in patients found to have early gastric cancer closely resemble peptic ulceration: 32% were being treated with H2 blockers and indeed benign gastric ulcer was present in 24 of 47 of these patients with early gastric carcinoma.
Undoubtedly uncertainties remain, but on the basis of our analysis we can say that some morphological features and patterns of evolution of disease may be identified as risk factors for gastric carcinoma though the magnitude of the risk is still unknown. These observations could form the basis for guidelines for follow up surveillance.
(i) Guided and site controlled multiple sample biopsies (six specimens) from the regions more likely to be involved in the process, antrum (3 cm from the pylorus), incisura angularis, and body, should be taken.
(ii) Standardised reporting to include the degree and activity of inflammation, glandular atrophy, and intestinal metaplasia types, dysplasia, and other possibly relevant features.
(iii) Surveillance: the frequency of screening cannot, at present, be suggested with any precision, though the evolution of metaplasia seems to be a long process and an interval of three to five years for follow up may be acceptable. If our hypothesis is correct, surveillance could focus more closely on patients with persistent quiescent chronic atrophic gastritis and type III intestinal metaplasia, and those with gastric ulcers which fail to heal. 
